In the United Kingdom, concerns about the consequences of genetic testing and the eligibility for life assurance have worried families wanting to pursue genetic testing for later onset disorders such as familial cancers and neurological disease. The recent history and development of the insurance and genetic testing guidelines in the UK is interesting and relevant, because it is the only country in Europe to have had a recent major change in insurance recommendations. Insurance companies have driven the changes, which culminated in the agreement of the UK Government and the Association of British Insurers on a five-year moratorium announced at the end of October 2001. This review details the events leading to the introduction ofa moratorium, and the implications for families with a family history of a familial cancer. BACKGROUND A family history of cancer is now universally recognised as a major risk factor for developing cancer and demand for appropriate clinical services is fuelled by publicity in both the popular media and the professional literature. Within the past few years, cancer genetic clinics have sprung up in almost every major medical centre and all are hard pressed to cope with the numbers of referralsl-31. The insurance implications ofgenetic testing are complex and this review serves to reflect recent changes in government policy and in the thinking of the insurance industry in the United Kingdom. The situation in the USA is different as within a private healthcare system, insurers often encourage or fund genetic testing as they can see the preventative value of such tests in helping initiate cancer Family history data has been used for years and is generally accepted by insurance companies although there may be considerable inaccuracy in family history data. Using such history without good validated reasons is bad practice and should be challenged -further evidence needs to be collected to demonstrate whether such use is really fair or effective. In the UK, 95-97% of life insurance policies are accepted at no increased premium. Only about 1% are declined, and 2-4% are rated upl' 1 12] . There is no analysis of these figures for specific diseases. The main reason for refusal or 'loaded' premiums is the above average sum assured, and not the type of 'high risk' individual assessed. Risks for insurers will be small if the policy value is low[131, for example under £100,000.
THE RECENT UK POLICY DEVELOPMENTS IN INSURANCE AND GENETIC TESTING
In the UK the main concern is about the consequences of cancer genetic testing on the eligibility for life assurance [14' 151. The recent history and development of the insurance and genetic testing situation in the UK is interesting and relevant, because it is the only country in Europe to have had a recent major change in insurance recommendations. Insurance companies have driven the changes. Before 1995, the insurance industry paid little attention to progression of genetic testing. A House of Commons Science and Technology Select Committee reported on human genetics in 1995, [16] and included insurance issues. The committee found a lack ofpublished research on underwriting and adverse selection, with the insurance industry relying on the principle ofthe 'right to underwrite'. Shortly after the publication of the report, the UK Government gave the ABI one year to formulate proposals that would meet demands for access to insurance. At the same time, they announced the formation of a Human Genetics Advisory Commission (HGAC). The HGAC was established in December 1996 as a non-statutory advisory body to report to the government on various developments in genetics. It concentrated on insurance as its first task. The insurance industry in 1997 announced the appointment of a genetics adviser and drafted a code of practice. The first HGAC report was published in December l997 ['3] . The report recommended a two-year moratorium on genetic testing. Its conclusions are shown in Table 1 . The Association of British The ABI code ofpractice for genetic testing came into effect in January 1998. The code had several important features (Table 2 ) and applied to all insurance, including life, permanent health, critical illness, and long-term care and medical expenses. Most 'relevant' UK insurance is predominantly life insurance linked to personal pensions, and property insurance (mortgage cover). As the UK National Health Service provides free health care, health insurance is less frequently purchased than in the USA, although there has been a recent increase in sales ofpersonal health insurance cover policies. The situation 5. An exception is made for policies greater than £500,000. as protection from significant financial loss. 6. Only genetic tests approved by the genetics and insurance committee (GAIC) should be taken onto account for these high value policies. There remains a need for an expert body of this kind. 7 . In view of the failings of self-regulation, independent enforcement of the moratorium will be needed. The HGC believes that legislation will be necessary to achieve this.
has not been introduced; however independent monitoring of the ABI code of conduct will take place possibly through an enhanced role for GAIC in monitoring both insurance compliance and customer complaints. It is also to review the composition of the GAIC committee with extension of its' membership. The moratorium has not been extended to use of family history data, and the whole moratorium will be reviewed after 3 years. An important note from the patients' perspective is that the use of negative test results is encouraged by the insurer subject to confirmation in most cases by a geneticist of the relevance of the result. Patients, and their clinicians, should be aware of the regulations on insurance and genetic testing, the relevant contents of the ABI report and the recent moratorium on insurance and genetic testing within the UK. Most of these issues are complex and patients with a history of familial cancer need access to a clinical genetics service either by direct telephone or clinic contact or through secondary contact via their medical practitioner or hospital clinician. This is particularly useful if the risk is being based on family history, as often patients' knowledge of their own family history of cancer may be inaccurate. The introduction of the recent moratorium and the safeguards contained both within it and by external monitoring ofthe genetic testing aspects by GAIC and the ethical and social aspects by HGC, is an encouraging step. Increased use of normal test results in setting normal premiums and industry competition should improve access to reasonable insurance cover for hereditary illnesses and as not all insurance companies belong to the ABI, good advice is to 'shop around' using an independent advisor who may be able to negotiate very competitive rates.
CONCLUSION
The rapidly evolving practice of clinical genetics is producing many questions to which we do not yet have clear answers. This is nowhere more apparent than in the genetics of common cancers, including breast cancer, which is the fastest growing area of genetic medicine. Worry about misuse of genetic test information by insurers is a real occurrence and the recent discussions between the Government and the insurance industry leading to their moratorium is to be welcomed. Little evidence exists on which to base a lot of risk assessment by insurers on either the predictive power of cancer genetic tests or on the use of family history as a rating factor. Further high quality actuarial research evidence will provide a better understanding of insurance risk estimation and allow better actuarial practice in calculation of insurance premiums in families with a history of cancer.
